公开(公告)号：US20240140915A1

公开(公告)日：2024-05-02

申请号：US18370519

申请日：2023-09-20

Applicant: Vividion Therapeutics, Inc.

Inventor： Shota Kikuchi ,  Betty Lam ,  Jason Green ,  Don Rogness ,  David Weinstein ,  Larry Burgess ,  Benjamin Horning ,  Kelsey Lamb ,  Zachary Owyang ,  Robert Malmstrom

IPC: C07D239/34 ,  A61P35/00 ,  C07D403/06 ,  C07K14/00

CPC classification number: C07D239/34 ,  A61P35/00 ,  C07D403/06 ,  C07K14/001

Abstract: Disclosed are compounds of Formula (I):




or pharmaceutically acceptable salts or solvates thereof, wherein R1, R3, X, Y, Z, and W are as defined herein. The compounds are, for example, inhibitors of WRN helicase and useful in treating a proliferative disease, such as cancer.

公开(公告)号：US20240067612A1

公开(公告)日：2024-02-29

申请号：US18218149

申请日：2023-07-05

Applicant: Vividion Therapeutics, Inc.

Inventor： Shota Kikuchi ,  Betty Lam ,  Jason Green ,  Don Rogness ,  David Weinstein ,  Larry Burgess ,  Benjamin Horning ,  Kelsey Lamb ,  Zach Owyang ,  Robert Malmstrom

IPC: C07D239/34 ,  C07D403/06 ,  C07K14/00 ,  A61P35/00

CPC classification number: C07D239/34 ,  C07D403/06 ,  C07K14/001 ,  A61P35/00

Abstract: Disclosed are compounds of Formula (I):






or pharmaceutically acceptable salts or solvates thereof, wherein R1, R3, X, Y, Z, and W are as defined herein. The compounds are, for example, inhibitors of WRN helicase and useful in treating a proliferative disease, such as cancer.

公开(公告)号：US10781239B2

公开(公告)日：2020-09-22

申请号：US16536227

申请日：2019-08-08

Applicant: Vividion Therapeutics, Inc. ,  The Scripps Research Institute

Inventor： David Weinstein ,  Benjamin F. Cravatt ,  Matthew Patricelli ,  Dean Stamos ,  Gabe Simon ,  Benjamin Horning ,  Ekaterina Vinogradova ,  Brian Nordin ,  Kristen Baltgalvis ,  Todd Kinsella

IPC: C07K14/47 ,  C07D211/94

Abstract: Disclosed herein are in vivo engineered cereblon protein and methods of making the same. The in vivo engineered cereblon protein can include a site-specific non-naturally occurring modification at cysteine 287 as set forth in SEQ ID NO:1, or cysteine 286 as set forth in SEQ ID NO:2 or 3, the modification comprising a moiety resulting from an in vivo Michael addition reaction between an exogenous Michael acceptor and the cysteine 287 as set forth in SEQ ID NO:1, or cysteine 286 as set forth in SEQ ID NO:2 or 3.

公开(公告)号：US12187685B2

公开(公告)日：2025-01-07

申请号：US18370519

申请日：2023-09-20

Applicant: Vividion Therapeutics, Inc.

Inventor： Shota Kikuchi ,  Betty Lam ,  Jason Green ,  Don Rogness ,  David Weinstein ,  Larry Burgess ,  Benjamin Horning ,  Kelsey Lamb ,  Zachary Owyang ,  Robert Malmstrom

IPC: C07D237/34 ,  A61P35/00 ,  C07D239/34 ,  C07D403/06 ,  C07K14/00

Abstract: Disclosed are compounds of Formula (I): or pharmaceutically acceptable salts or solvates thereof, wherein R1, R3, X, Y, Z, and W are as defined herein. The compounds are, for example, inhibitors of WRN helicase and useful in treating a proliferative disease, such as cancer.

公开(公告)号：US11771689B2

公开(公告)日：2023-10-03

申请号：US16950697

申请日：2020-11-17

Applicant: Vividion Therapeutics, Inc. ,  The Scripps Research Institute

Inventor： Benjamin F. Cravatt ,  Matthew Patricelli ,  Dean Stamos ,  Gabe Simon ,  Benjamin Horning ,  David Weinstein ,  Ekaterina Vinogradova

IPC: A61K31/44 ,  A61K31/50 ,  A61K31/445 ,  A61K31/501 ,  A61K31/439 ,  A61K31/397 ,  A61K31/4545

CPC classification number: A61K31/445 ,  A61K31/397 ,  A61K31/439 ,  A61K31/4545 ,  A61K31/501

Abstract: Disclosed herein are compositions and methods for modulating cereblon neosubstrates. A small molecule modulator of Formula (I*), or a pharmaceutically acceptable salt or solvate thereof can be used to modulate cereblon neosubstrates.